UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
12.03
+0.95 (8.57%)
At close: Jun 13, 2025, 4:00 PM
12.15
+0.12 (1.00%)
After-hours: Jun 13, 2025, 7:59 PM EDT
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$390,940
Profits / Employee
-$589,068
Market Cap
554.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
URGN News
- 21 hours ago - UroGen Pharma: Lessons Learned And Future Outlook - Seeking Alpha
- 1 day ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - GlobeNewsWire
- 1 day ago - U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
- 1 day ago - US FDA approves Urogen's bladder cancer drug - Reuters
- 3 days ago - UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation - Seeking Alpha
- 4 days ago - URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%? - GlobeNewsWire
- 4 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN - GlobeNewsWire
- 6 days ago - URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN) - GlobeNewsWire